Skip to main content

Table 3 Medical resource use for disease management by health state (Source of costs: NHS reference costs 2013–2014 [29])

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

  On treatment (first- or second-line) Stable disease (off treatment) At time of progression Progressed Unit cost
Full blood count 3 per treatment cycle 1 per 2–3 monthsa 1 0 £3.00
Biochemistry 3 per treatment cycle 1 per 2–3 monthsa 1 0 £1.18
Blood glucose 3 per treatment cycle 0 0 0 £1.18
Computerised tomography scan In treatment Cycles 1, 3 and 6 0 1 0 £80.00
Haematologist visit In treatment Cycles 1, 3 and 6 1 per 2–3 monthsa 1 1 per 2–3 monthsa £150.06
  1. Abbreviations: NHS National Health Service
  2. aThis has been applied to the model as once every 11 weeks